Patents by Inventor Shengjian Li
Shengjian Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240125705Abstract: The present invention provides, among other things, devices, kits, apparatus, and methods for rapid homogenous cell staining and imaging. Particularly, in some embodiments, the present invention can immunochemically stain a cell or a tissue in less than 60 seconds without washing. In some embodiments, the present invention stains and observes analyte (protein or nucleic acid) inside a cell in 60 seconds without washing.Type: ApplicationFiled: December 19, 2023Publication date: April 18, 2024Applicant: Essenlix CorporationInventors: Stephen Y. CHOU, Wei DING, Ji LI, Shengjian Cai, Yufan Zhang, Jia Peng
-
Patent number: 9919998Abstract: The invention provides compounds having activity as bacterial RNA polymerase inhibitors and antibacterial agents, as well as compositions comprising the compounds and methods for their use. Specifically, phenylalanineamide and tyrosinamide compounds are disclosed that have inhibitory activity toward mycobacterium tuberculosis RNA polymerase. Use of these compounds in the treatment or prevention of M. tuberculosis infections in a mammal, is disclosed.Type: GrantFiled: February 6, 2015Date of Patent: March 20, 2018Assignee: Rutgers, The State University of New JerseyInventors: Richard H. Ebright, Yon W. Ebright, Soma Mandal, Richard Wilde, Shengjian Li
-
Publication number: 20160347708Abstract: The invention provides compounds having activity as bacterial RNA polymerase inhibitors and antibacterial agents, as well as compositions comprising the compounds and methods for their use. Specifically, phenylalanineamide and tyrosinamide compounds are disclosed that have inhibitory activity toward mycobacterium tuberculosis RNA polymerase. Use of these compounds in the treatment or prevention of M. tuberculosis infections in a mammal, is disclosed.Type: ApplicationFiled: February 6, 2015Publication date: December 1, 2016Inventors: Richard H. Ebright, Yon W. Ebright, Soma Mandal, Richard Wilde, Shengjian Li
-
Patent number: 7638518Abstract: The present invention is directed to novel substituted pyrazole compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.Type: GrantFiled: October 12, 2007Date of Patent: December 29, 2009Assignee: Janssen PharmaceuticaInventors: George Chiu, Yang Yu, Ronghui Lin, Shengjian Li, Peter J. Connolly
-
Patent number: 7541367Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.Type: GrantFiled: May 31, 2006Date of Patent: June 2, 2009Assignee: Janssen Pharmaceutica, N.V.Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
-
Patent number: 7517885Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: GrantFiled: June 14, 2006Date of Patent: April 14, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
-
Publication number: 20090048249Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.Type: ApplicationFiled: May 31, 2006Publication date: February 19, 2009Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
-
Patent number: 7482348Abstract: The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: GrantFiled: March 15, 2006Date of Patent: January 27, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton
-
Patent number: 7470711Abstract: The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.Type: GrantFiled: March 15, 2006Date of Patent: December 30, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton
-
Patent number: 7459557Abstract: The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: GrantFiled: June 12, 2006Date of Patent: December 2, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
-
Publication number: 20080153844Abstract: The present invention is directed to novel substituted pyrazole compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.Type: ApplicationFiled: October 12, 2007Publication date: June 26, 2008Inventors: George Chiu, Yang Yu, Ronghui Lin, Shengjian Li, Peter J. Connolly
-
Patent number: 7345042Abstract: The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.Type: GrantFiled: June 28, 2004Date of Patent: March 18, 2008Assignee: Schering CorporationInventors: Anandan Palani, Sherry A. Shapiro, Hubert B. Josien, Thomas A. Bara, John W. Clader, Pradeep B. Pushpavanam, Shengjian Li, Mark D. McBriar
-
Publication number: 20070123542Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: ApplicationFiled: June 14, 2006Publication date: May 31, 2007Inventors: George Chiu, Peter Connolly, Jessica Liu, Steven Middleton, Virginia Pulito, Shengjian Li
-
Publication number: 20070093500Abstract: The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: ApplicationFiled: June 12, 2006Publication date: April 26, 2007Inventors: George Chiu, Peter Connolly, Jessica Liu, Steven Middleton, Virginia Pulito, Shengjian Li
-
Publication number: 20060223825Abstract: The present invention relates to piperazine substituted cyclohexane- 1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.Type: ApplicationFiled: March 15, 2006Publication date: October 5, 2006Inventors: George Chiu, Shengjian Li, Peter Connolly, Virginia Pulito, Jingchun Liu, Steven Middleton
-
Publication number: 20060217419Abstract: The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.Type: ApplicationFiled: March 15, 2006Publication date: September 28, 2006Inventors: George Chiu, Shengjian Li, Peter Connolly, Virginia Pulito, Jingchun Liu, Steven Middleton
-
Publication number: 20060173015Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective ?1a/?1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.Type: ApplicationFiled: October 28, 2005Publication date: August 3, 2006Inventors: George Chiu, Shengjian Li, Peter Connolly, Virginia Pulito, Jessica Liu, Steven Middleton
-
Publication number: 20050004121Abstract: The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.Type: ApplicationFiled: June 28, 2004Publication date: January 6, 2005Inventors: Anandan Palani, Sherry Shapiro, Hubert Josien, Thomas Bara, John Clader, Pradeep Pushpavanam, Shengjian Li, Mark McBriar
-
Patent number: 6472394Abstract: Disclosed are compounds represented by structural formula I: or a pharmaceutically acceptable salt, ester or solvate thereof, wherein W is R1—CR3R12NR4C(O)— or R11C(O)NR4—; the dotted line is an optional double bond; X is —CHR8—, —C(O)—, or —C(═NOR9)—; Y is R1 is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkyl-alkyl; R2 is optionally substituted aryl or heteroaryl; R3 is alkyl, aryl or heteroaryl; R4 and R12 are H or alkyl; R8 is H, alkyl or alkoxyalkyl; R9 is H, alkyl or arylalkyl; R10 is H, alkyl or aryl; R11 is or, when R2 is R6-heteroaryl or R10 is not H, R11 can also be R5-phenylalkyl; n is 1-3 and m is 1-5; and R14 is 1-3 substituents selected from H, alkyl, halogen, —OH, alkoxy and CF3; and pharmaceutical compositions containing the compounds and methods of using the compounds in the trType: GrantFiled: December 17, 2001Date of Patent: October 29, 2002Assignee: Schering CorporationInventors: Brian A. McKittrick, Jing Su, John W. Clader, Shengjian Li, Guihau Guo